Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

1.

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.

Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P.

Ann Rheum Dis. 2014 Jun 18. pii: annrheumdis-2014-205198. doi: 10.1136/annrheumdis-2014-205198. [Epub ahead of print]

PMID:
24942382
[PubMed - as supplied by publisher]
Free Article
2.

GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting.

Coates LC, Ritchlin CT, Kavanaugh AF.

J Rheumatol. 2014 Jun;41(6):1237-9. doi: 10.3899/jrheum.140179.

PMID:
24882861
[PubMed - in process]
3.

Clinical question: are non-steroidal anti-inflammatories superior to acetaminophen for sprains/strains?

Wheeler H, Vonfeldt K, Kavanaugh A, Owens T.

J Okla State Med Assoc. 2014 Mar;107(3):109-10. Review. No abstract available.

PMID:
24800464
[PubMed - indexed for MEDLINE]
4.

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A.

Ann Rheum Dis. 2014 Apr 26. doi: 10.1136/annrheumdis-2013-204902. [Epub ahead of print]

PMID:
24748630
[PubMed - as supplied by publisher]
Free Article
5.

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.

Kavanaugh A, Wells AF.

Rheumatology (Oxford). 2014 Apr 10. [Epub ahead of print]

PMID:
24729402
[PubMed - as supplied by publisher]
6.

Editorial: pregnancy and rheumatoid arthritis - do not let the perfect become the enemy of the good.

Cush JJ, Kavanaugh A.

Curr Opin Rheumatol. 2014 May;26(3):299-301. doi: 10.1097/BOR.0000000000000061. No abstract available.

PMID:
24667288
[PubMed - in process]
7.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.

Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4.

PMID:
24595547
[PubMed - in process]
Free PMC Article
8.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA.

Arthritis Res Ther. 2014 Mar 4;16(2):R60. [Epub ahead of print]

PMID:
24588936
[PubMed - as supplied by publisher]
Free PMC Article
9.

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC.

J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30. doi: 10.1016/j.jaad.2013.12.018. Epub 2014 Feb 24.

PMID:
24576585
[PubMed - indexed for MEDLINE]
10.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups.

Ann Rheum Dis. 2014 Jun;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741. Epub 2014 Feb 19.

PMID:
24553909
[PubMed - in process]
Free PMC Article
11.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

PMID:
24482301
[PubMed - in process]
Free PMC Article
12.

Recurrent annular peripheral choroidal detachment after trabeculectomy.

Liu S, Sun LL, Kavanaugh AS, Langford MP, Liang C.

Case Rep Ophthalmol. 2013 Oct 24;4(3):192-8. doi: 10.1159/000356166. eCollection 2013.

PMID:
24348402
[PubMed]
Free PMC Article
13.

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A.

Ann Rheum Dis. 2013 Dec 16. doi: 10.1136/annrheumdis-2013-204195. [Epub ahead of print]

PMID:
24344160
[PubMed - as supplied by publisher]
Free Article
14.

Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.

Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.

J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1.

PMID:
24293583
[PubMed - in process]
Free Article
15.

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.

J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.

PMID:
24241487
[PubMed - in process]
Free Article
16.

Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.

Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S28-32. Epub 2013 Oct 3. Review.

PMID:
24129133
[PubMed - indexed for MEDLINE]
17.

The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.

Kavanaugh A, Smolen JS.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S19-21. Epub 2013 Oct 3.

PMID:
24129131
[PubMed - indexed for MEDLINE]
18.

Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.

Pincus T, Braun J, Kavanaugh A, Smolen JS.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S1-3. Epub 2013 Oct 3. No abstract available.

PMID:
24129127
[PubMed - indexed for MEDLINE]
19.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.

Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Erratum in: Lancet. 2014 Jan 25;383(9914):308.

PMID:
24168956
[PubMed - indexed for MEDLINE]
20.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.

Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G.

J Clin Aesthet Dermatol. 2013 Sep;6(9 Suppl):S2-S20. No abstract available.

PMID:
24167640
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk